|
deCODE genetics, Inc. - Comparative Business Analysis Snapshot
Business Description
deCODE genetics, Inc.. The Group's principal activity is to develop and market products to improve the treatment, diagnosis and prevention of common diseases. It applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. Its lead drug development programs include: DG041 for the prevention of arterial thrombosis. The products include deCODE T2TM, deCODE AFTM, deCODE MITM, deCODEmeTM, deCODEProstateCancerTM, deCODE GlaucomaTM, deCODE BreastCancerTM. Other DNA-based risk diagnostic tests currently in development include: melanoma, basal cell cancer, bladder cancer and lung cancer.
Competitor Analysis
This analysis compares deCODE genetics, Inc. with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
